Treatment of impaired cognitive flexibility with TrkB receptor antagonists
AssigneesThe Florida State University Research Foundation, Inc., The General Hospital Corporation
InventorsPradeep G. Bhide, Dierdre M. McCarthy, Joseph Biederman, Thomas J. Spencer
Life of this patent
Estimating the term…
Abstract
The cognitive flexibility of a subject may be improved by administering a therapeutically effective amount of a TrkB receptor antagonist to the subject in need thereof. The TrkB receptor antagonist compound may be administered in a pharmaceutical dosage form.
Claims7
A method of treating impaired cognitive flexibility, the method comprising administering to a subject having impaired cognitive flexibility a therapeutically effective amount of a selective tyrosine kinase B (TrkB) receptor antagonist compound, the therapeutically effective amount being sufficient to improve cognitive flexibility in the subject;
- wherein the selective TrkB receptor antagonist compound does not inhibit tyrosine kinase A (TrkA) or tyrosine kinase C (TrkC) receptors;
- wherein the subject is identified as having at least one of attention deficit hyperactivity disorder (ADHD), autism spectrum disorder, and Asperger's syndrome;
- and
- wherein the TrkB receptor antagonist compound is at least one compound selected from (a) ANA-12, (b) an ANA-12 based compound, and (c) a pharmaceutically acceptable salt of compound (a) or (b), wherein ANA-12 comprises the formula
Dependencies are inferred from the claim text.